ASCO 2015 Update on Gastrointestinal Cancer: Checkpoint Inhibition, Multimodality Strategies and Secondary Prevention

Por Semrad, Thomas J.
Publicado no Surg Oncol (2015)

Molecular testing to optimize therapeutic decision making in advanced colorectal cancer

Por Semrad, Thomas J., Kim, Edward J.
Publicado no J Gastrointest Oncol (2016)

Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience

Por Semrad, Thomas J., Gandara, David R., Lara, Primo N.
Publicado em 2011

Phase II clinical trials on Investigational drugs for the Treatment of Pancreatic Cancers

Por Kim, Edward J., Semrad, Thomas J., Bold, Richard J.
Publicado no Expert Opin Investig Drugs (2015)

Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence based Approach Using Clinical Trial Findings

Por Semrad, Thomas J., Fahrni, Ana Rodriguez, Gong, I-Yeh, Khatri, Vijay P.
Publicado no Ann Surg Oncol (2015)

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

Por Semrad, Thomas J., Eddings, Courtney, Dutia, Mrinal P., Christensen, Scott, Lara, Primo N.
Publicado em 2013

Initial Treatment Patterns in Younger Adult Patients with Differentiated Thyroid Cancer in California

Por Semrad, Thomas J., Semrad, Alison M., Farwell, D. Gregory, Chen, Yingjia, Cress, Rosemary
Publicado no Thyroid (2015)

Geographic Variation of Racial/Ethnic Disparities in Colorectal Cancer Testing Among Medicare Enrollees

Por Semrad, Thomas J., Tancredi, Daniel J., Baldwin, Laura-Mae, Green, Pamela, Fenton, Joshua J.
Publicado no Cancer (2011)

Are there disparities in the presentation, treatment and outcomes of patients diagnosed with medullary thyroid cancer?—An analysis of 634 patients from the California Cancer Regist...

Por Cox, Christine, Chen, Yingjia, Cress, Rosemary, Semrad, Alison M., Semrad, Thomas, Gosnell, Jessica E., Campbell, Michael J.
Publicado no Gland Surg (2016)

Feasibility Study of Intra-patient Sorafenib Dose-Escalation or Re-Escalation in Patients with Previously Treated Advanced Solid Tumors

Por Semrad, Thomas J., Eddings, Courtney, Pan, Chong-Xian, Lau, Derick H., Gandara, David, Beckett, Laurel, Lara, Primo N.
Publicado em 2011

Disease control rate at 8 weeks predicts subsequent survival in platinum-treated extensive stage small cell lung cancer: Results from the Southwest Oncology Group (SWOG) database

Por Lara, Primo N., Moon, James, Redman, Mary W., Semrad, Thomas J., Kelly, Karen, Allen, Jeffrey, Gitlitz, Barbara, Mack, Philip C., Gandara, David R.
Publicado no Clin Lung Cancer (2015)

Relevance of platinum sensitivity status in relapsed/refractory extensive stage small cell lung cancer (ES-SCLC) in the modern era: A patient level analysis of SWOG trials

Por Lara, Primo N., Moon, James, Redman, Mary W., Semrad, Thomas J., Kelly, Karen, Allen, Jeffrey W., Gitlitz, Barbara J., Mack, Philip C., Gandara, David R.
Publicado no J Thorac Oncol (2015)

Pharmacodynamic Separation of Gemcitabine and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer: Therapeutic and Biomarker Results

Por Semrad, Thomas, Barzi, Afsaneh, Lenz, Heinz-Josef, Hutchins, Irene M., Kim, Edward J., Gong, I-Yeh, Tanaka, Michael, Beckett, Laurel, Holland, William, Burich, Rebekah A., Snyder-Solis, Leslie, Mack, Philip, Lara, Primo N.
Publicado no Int J Clin Oncol (2014)

Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors

Por Tomlinson, Benjamin K., Thomson, James A., Bomalaski, John S., Diaz, Monica, Akande, Taiwo, Mahaffey, Nichole, Li, Tianhong, Dutia, Mrinal P., Kelly, Karen, Gong, I-Yeh, Semrad, Thomas, Gandara, David R., Pan, Chong-Xian, Lara, Primo N.
Publicado no Clin Cancer Res (2015)